This allows to link your profile to this item. If you have authored this item and are not yet registered with RePEc, we encourage you to do it here.
MARTA GUERRAS HOW TO
See general information about how to correct material in RePEc.įor technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:18:y:2021:i:9:p:4804-:d:546912. You can help correct errors and omissions. Suggested CitationĪll material on this site has been provided by the respective publishers and authors. In certain countries, it was also associated with older age, CAI and being undertested. Self-testing was highly valued, especially among individuals who were not open about their sexual behaviors with men. The internet (32.8%) was the preferred place to acquire a self-testing kit and primary care (34.0%) for confirmation purposes. Not being open about one’s sexual behaviors with men was associated with choosing self-testing as the preferred option, except in Greece older age in Greece and Spain reporting condomless anal intercourses (CAI) in Germany and Portugal reporting one previous test in Greece between 2 and 5 in Spain and with having been tested ≥ 12 months ago in Germany, Portugal and Spain. For those choosing it as their preferred option, we assessed the preferred settings to acquire a self-testing kit and to confirm a reactive result.
We used Poisson regression to identify factors associated with choosing self-testing as the preferred testing option. In 2016, we recruited an online sample of 3725 HIV-negative MSM. We analyzed men who have sex with men (MSM) from Denmark, Germany, Greece, Portugal and Spain to identify who would choose HIV self-testing as their preferred testing method and assessed their preferred setting to acquire a self-testing kit and to confirm a reactive result. (EURO HIV EDAT Group are listed in Acknowledgments.) (Departamento de Salud Pública y Materno-Infantil, Universidad Complutense de Madrid, 28040 Madrid, SpainĬIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain)Įscuela Nacional de Sanidad, Instituto de Salud Carlos III, 28029 Madrid, Spain) (Checkpoint Athens, 105 54 Athens, Greece) (GAT-Grupo de Ativistas em Tratamentos, 1000-228 Lisboa, Portugal) (AIDS Hilfe NRW e.V., 10963 Berlin, Germany) (Escuela Nacional de Sanidad, Instituto de Salud Carlos III, 28029 Madrid, Spain)ĭepartament de Salut, Centre Estudis Epidemiologics sobre les Infeccions de Transmissio Sexual i Sida de Catalunya (CEEISCAT), Generalitat de Catalunya, 08005 Badalona, Spain) (CIBER Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, SpainĬentro Nacional de Epidemiología, Instituto de Salud Carlos III, 28029 Madrid, Spain) (Gerencia de Atención Primaria de Valladolid Este, Gerencia Regional de Salud de Castilla y León (SACYL), 47010 Valladolid, Spain) (Departamento de Salud Pública y Materno-Infantil, Universidad Complutense de Madrid, 28040 Madrid, Spain)
0 kommentar(er)
